Samsung Biologics announced on the 28th that it participated in the BioProcess International Conference “2026 BioProcess International (BPI)” held in Boston, United States, where it presented its strategies for innovation in biopharmaceutical manufacturing.

BPI is a global event that shares the latest technologies and discusses partnerships across the entire spectrum of biopharmaceutical development, production, and analytics. It is hosted and organized by Informa Connect, a UK-based business information and exhibition company. In addition to Boston in the United States, the conference is also held in Europe and Asia, with the Boston main event serving as the flagship program of “Biotech Week Boston,” organized by Informa. Informa is a company specializing in knowledge and exhibitions, and Informa Connect is its dedicated events division. This year’s Boston BPI ran for four days from the 22nd to the 25th (local time). More than 250 companies and over 3,000 experts from the global bio industry are reported to have attended.

Samsung Biologics has operated its own booth at BPI for nine consecutive years since 2018. At the booth, it showcased its capabilities to support the entire biopharmaceutical lifecycle, from contract research organization (CRO) and contract development organization (CDO) to contract manufacturing organization (CMO). In particular, using a wall graphic in the booth, the company highlighted its core competencies, including ▲Samsung Organoids ▲differentiated CDO capabilities ▲multi-modality manufacturing.

The company also conducted expert presentations and poster sessions. Executive Vice President Lee Tae-hee, Head of the Antibody Cell Purification Process Development Team, gave a presentation under the theme “From Complexity to Confidence.” Based on integrated chemistry, manufacturing and controls (CMC), Lee disclosed a case in which the company designed molecule-specific customized processes to shorten the development period from the existing 13 months to 9.5 months while securing high quality.

In the ongoing poster sessions, Samsung Biologics also introduced a range of its process innovation achievements. Kim Young-hee, Head of the Cell Line Development Group, presented strategies under the theme “A Streamlined Cell Line Development Platform for Complex Molecules,” demonstrating how to simultaneously control drug quality and efficacy from the early stages of cell line development. Lee So-jung, Head of the Upstream Process Development Group, unveiled a strategy using the intensified upstream processing platform “S-Tensify” to increase cell density during cultivation, thereby doubling the titer while maintaining top-level quality.

Samsung Biologics also participated in the “Cell & Gene Therapy International” conference, which was held concurrently at the venue. Through the conference, the company proposed criteria for accurately measuring the quality of advanced viral therapeutics. Garcia Abigail, Head of the AAV (Adeno-Associated Virus) Technology Group, shared a full capsid analysis strategy that evaluates the proportion of therapeutic genes correctly packaged within the adeno-associated virus, presenting specific guidelines to maximize the efficacy and stability of gene therapies.

AAV is drawing significant attention from the biopharmaceutical and medical communities as a key delivery vector for gene therapies. It is known to be safe for humans, as it does not cause disease in the human body and cannot self-replicate or proliferate. Commercialized AAV gene therapies include Zolgensma (active ingredient: onasemnogene abeparvovec) for the treatment of spinal muscular atrophy (SMA) and Luxturna (voretigene neparvovec) for treating blindness caused by congenital retinal genetic disorders.

James Choi, Executive Vice President and Head of Corporate Affairs at Samsung Biologics, said, “Through BPI, we showcased our unrivaled capabilities in full-lifecycle biopharmaceutical support from CRO to CDO and CMO, as well as our differentiated technological competitiveness,” adding, “We will continue to further solidify our position in the global bio market with increasingly sophisticated technologies and services.”

Popular News